alpha-aminopyridine has been researched along with Androgen-Independent Prostatic Cancer in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aggarwal, R; Carneiro, BA; de Kouchkovsky, I; Fong, L; Friedlander, T; Lewis, C; Paris, PL; Phone, A; Rao, A; Ryan, CJ; Small, EJ; Szmulewitz, RZ; Zhang, L | 1 |
| Andersen, D; Dickson, A; Edwards, J; Holmes, E; Leung, HY; Markert, E; McAllister, MJ; McCall, P; Underwood, MA | 1 |
| Alumkal, JJ; Armstrong, AJ; Beer, TM; Bitting, RL; George, DJ; Halabi, S; Healy, P; Hobbs, C; Kephart, J; Mundy, K; Slottke, R; Soleau, CF; Winters, C; Yu, EY | 1 |
| Bollag, G; Guan, W; Hu, J; Tan, P; Tang, Z; West, BL; Wu, L; Xu, H; Yang, L | 1 |
| Castellano, D; Chakravartty, A; Chi, KN; Csonka, D; de Bono, J; Dirix, L; Fizazi, K; Gravis, G; Machiels, JP; Maier, J; Massard, C; Mellado, B; Mita, A; Turri, S | 1 |
3 trial(s) available for alpha-aminopyridine and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Cyclin-Dependent Kinase 4; Docetaxel; Febrile Neutropenia; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Purines; Treatment Outcome | 2022 |
Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Humans; Male; Middle Aged; Morpholines; Nitriles; Phenylthiohydantoin; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors | 2017 |
Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Asthenia; Chills; Diarrhea; Fever; Humans; Hyperglycemia; Imidazoles; Kallikreins; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quinolines; Stomatitis; Vomiting | 2017 |
2 other study(ies) available for alpha-aminopyridine and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Androgen receptor phosphorylation at serine 81 and serine 213 in castrate-resistant prostate cancer.
Topics: Aged; Aminopyridines; Androgen Receptor Antagonists; Benzamides; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Humans; Male; Morpholines; Nitriles; Phenylthiohydantoin; Phosphatidylinositol 3-Kinase; Phosphorylation; Prognosis; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Serine; Signal Transduction; Survival Rate | 2020 |
Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line; Cytokines; Docetaxel; Humans; Macrophages; Male; Mice; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor | 2019 |